Latest & Greatest

Latest & Greatest

Recent developments in the field of hematology/oncology, including drug approvals, policy updates, and clinical trial results

FDA Approves Caplacizumab-yhdp for Acquired TTP

Caplacizumab-yhdp, a bivalent anti–von Willebrand factor nanobody, was approved for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with...

Liquid Biopsy Test Cleared for Use in CML

The U.S. Food and Drug Administration approved the QXDx AutoDG ddPCR System, a liquid biopsy test designed to precisely and reproducibly monitor molecular response...

New Treatment Approved for Hemophilia A

The U.S. Food and Drug Administration approved turoctocog alfa pegol, an extended half-life factor VIII (FVIII) molecule formerly known as N8-GP, for the treatment...

FDA Warns Consumers About “Young Blood” Plasma Infusions

Responding to the rising popularity of “anti-aging” plasma infusions from young adults, the U.S. Food and Drug Administration (FDA) has warned consumers that the...

Dasatinib Granted Approval for Pediatric Indication

The FDA expanded the indication of dasatinib, a second-generation tyrosine kinase inhibitor, to include the treatment of pediatric patients (≥1 year of age) with...

Bristol-Myers Squibb to Purchase Celgene

Bristol-Myers Squibb (BMS) agreed to buy Celgene for $74 billion, making it the second-biggest purchase in the pharmaceutical and biotechnology industry and continuing a...

FDA Updates Guidance on Rare Disease Drug Development

The U.S. Food and Drug Administration (FDA) released a revised draft guidance for sponsors developing “orphan drugs” for the treatment or prevention of rare...

Congress Passes Bipartisan Sickle Cell Bill

The U.S. Congress recently passed the Sickle Cell Disease and Other Heritable Blood Disorders Research, Surveillance, Prevention, and Treatment Act of 2018, bipartisan legislation...

Tagraxofusp-erzs Becomes First Approval for BPDCN

The U.S. Food and Drug Administration approved tagraxofusp-erzs for the treatment of adults and children (≥2 years of age) with blastic plasmacytoid dendritic cell...

FDA Approves Ravulizumab for PNH

The U.S. Food and Drug Administration (FDA) approved ravulizumab, a long-acting complement inhibitor that prevents hemolysis, for the treatment of adults with paroxysmal nocturnal...
Advertisement

Current Issue

August 2019, Volume 5, Issue 10

August 2019, Volume 5, Issue 10

This issue features a debate about gun control as a health care issue, a look at blood services in Israel and Palestine, and more.